<main class="html-publication" lang="en" role="main">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link brand__border-color" href="/government/organisations/nhs-commissioning-board">
      <span class="gem-c-organisation-logo__name">NHS England</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>


  <h1 class="gem-c-title__text govuk-heading-xl">
    Prenatal diagnosis
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 5 July 2022</p>

  </header>




  <section class="gem-c-devolved-nations">
    <h2 class="govuk-heading-s govuk-!-margin-bottom-0">
      Applies to England
</h2>
</section>

<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">
    <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
        <nav aria-label="Contents" class="gem-c-contents-list" data-module="gem-track-click" role="navigation">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 1" data-track-category="contentsClicked" data-track-label="#quantitative-fluorescence-polymerase-chain-reaction-qf-pcr-testing" data-track-options="{&quot;dimension29&quot;:&quot;\n1. Quantitative fluorescence polymerase chain reaction (QF-PCR) testing&quot;}" href="#quantitative-fluorescence-polymerase-chain-reaction-qf-pcr-testing"><span class="gem-c-contents-list__number">1. </span><span class="gem-c-contents-list__numbered-text">Quantitative fluorescence polymerase chain reaction (QF-PCR) testing</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 2" data-track-category="contentsClicked" data-track-label="#qf-pcr-results" data-track-options="{&quot;dimension29&quot;:&quot;\n2. \nQF-PCR results&quot;}" href="#qf-pcr-results"><span class="gem-c-contents-list__number">2. </span><span class="gem-c-contents-list__numbered-text">QF-PCR results</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 3" data-track-category="contentsClicked" data-track-label="#pnd-following-a-higher-chance-result-from-the-combined-or-quadruple-test-or-nipt" data-track-options="{&quot;dimension29&quot;:&quot;\n3. \nPND following a higher chance result from the combined or quadruple test or NIPT\n&quot;}" href="#pnd-following-a-higher-chance-result-from-the-combined-or-quadruple-test-or-nipt"><span class="gem-c-contents-list__number">3. </span><span class="gem-c-contents-list__numbered-text">PND following a higher chance result from the combined or quadruple test or NIPT</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 4" data-track-category="contentsClicked" data-track-label="#pnd-following-unexpected-structural-findings-on-the-20-week-screening-scan" data-track-options="{&quot;dimension29&quot;:&quot;\n4. \nPND following unexpected structural findings on the 20-week screening scan&quot;}" href="#pnd-following-unexpected-structural-findings-on-the-20-week-screening-scan"><span class="gem-c-contents-list__number">4. </span><span class="gem-c-contents-list__numbered-text">PND following unexpected structural findings on the 20-week screening scan</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 5" data-track-category="contentsClicked" data-track-label="#prenatal-diagnosis-results" data-track-options="{&quot;dimension29&quot;:&quot;\n5. Prenatal diagnosis results&quot;}" href="#prenatal-diagnosis-results"><span class="gem-c-contents-list__number">5. </span><span class="gem-c-contents-list__numbered-text">Prenatal diagnosis results</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 6" data-track-category="contentsClicked" data-track-label="#pregnancy-outcome-audit" data-track-options="{&quot;dimension29&quot;:&quot;\n6. Pregnancy outcome audit&quot;}" href="#pregnancy-outcome-audit"><span class="gem-c-contents-list__number">6. </span><span class="gem-c-contents-list__numbered-text">Pregnancy outcome audit</span></a>

        </li>
    </ol>
</nav>
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-93b6a51b518ff99714a1aa2a7d2162735c155ec3cb073c75fb88b2a332fa83d3.png">
</p>
<p>
  Â© Crown copyright 2022
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/fetal-anomaly-screening-programme-handbook/prenatal-diagnosis
</p>


    </div>
  </div>

  <div class="main-content-container">
    <div class="gem-c-govspeak-html-publication">
  
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
    
      <div class="govspeak">
<p>For naming conventions used throughout this guidance and other general information, please read the <a class="govuk-link" href="/government/publications/fetal-anomaly-screening-programme-handbook/overview">Overview</a> page.</p>

<hr>

<p>Women are offered and can choose to have prenatal diagnosis (<abbr title="prenatal diagnosis">PND</abbr>) in the following 2 situations:</p>

<ul>
  <li>a higher chance result for <a class="govuk-link" href="/government/publications/fetal-anomaly-screening-programme-handbook/overview#Downs">trisomy 21 (<abbr title="trisomy 21 (Down's syndrome)">T21</abbr>)</a>, <a class="govuk-link" href="/government/publications/fetal-anomaly-screening-programme-handbook/overview#Edwards">trisomy 18 (<abbr title="trisomy 18 (Edward's syndrome)">T18</abbr>)</a> or <a class="govuk-link" href="/government/publications/fetal-anomaly-screening-programme-handbook/overview#Pataus">trisomy 13 (<abbr title="trisomy 13 (Patau's syndrome)">T13</abbr>)</a> from the combined or quadruple test or non-invasive prenatal testing (<abbr title="non-invasive pre-natal testing">NIPT</abbr>)</li>
  <li>unexpected structural findings on the <a class="govuk-link" href="https://www.gov.uk/government/publications/fetal-anomaly-screening-programme-handbook/20-week-screening-scan">20-week screening scan</a>
</li>
</ul>

<p>In this guidance, <abbr title="prenatal diagnosis">PND</abbr> refers to <a class="govuk-link" href="https://www.gov.uk/government/publications/cvs-and-amniocentesis-diagnostic-tests-description-in-brief/nhs-fetal-anomaly-screening-programme-chorionic-villus-sampling-cvs-and-amniocentesis-information-for-parents">chorionic villus sampling (<abbr title="chorionic villus sampling">CVS</abbr>) and amniocentesis</a>. These procedures should only be performed by specially trained healthcare professionals. Women may be required to attend a tertiary-level centre.</p>

<p><abbr title="chorionic villus sampling">CVS</abbr> is a transabdominal or sometimes transcervical procedure performed under continuous ultrasound guidance. It is usually performed from 11 to 14 weeks of pregnancy but can be done later. A sample of placental tissue is obtained for chromosomal or genetic analysis.</p>

<p>Amniocentesis is a procedure performed under continuous ultrasound guidance. It is usually performed from 15 to 20 weeks of pregnancy but can be done later. A sample of amniotic fluid is obtained for chromosomal or genetic analysis.</p>

<p>One in 200 women who have a <abbr title="chorionic villus sampling">CVS</abbr> or amniocentesis will miscarry.</p>

<h2>
<span class="number">1. </span>Quantitative fluorescence polymerase chain reaction (<abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr>) testing</h2>

<p>Samples from <abbr title="chorionic villus sampling">CVS</abbr> and amniocentesis procedures are sent to the genomic laboratory for <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> testing. <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> testing detects the evidence of <abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> and <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr>.</p>

<p><abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> testing is based on the amplification of chromosome-specific deoxyribonucleic acid (<abbr title="deoxyribonucleic acid">DNA</abbr>) sequences. The amplified <abbr title="deoxyribonucleic acid">DNA</abbr> segments can be visualised and quantified as peak areas on automated scanners.</p>

<p>Women should be informed of the usual reporting time for <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> results before the <abbr title="prenatal diagnosis">PND</abbr> procedure.</p>

<p><a class="govuk-link" href="https://www.gov.uk/government/publications/fetal-anomaly-screening-programme-standards/standards-valid-from-1-april-2018#fasp-s09-diagnosisintervention-diagnostic-tests-fetal-anomaly-screening">Diagnosis/intervention standard <abbr title="fetal anomaly screening programme">FASP</abbr>-S09</a> outlines test turnaround timeframes for <abbr title="prenatal diagnosis">PND</abbr>.</p>

<h2>
<span class="number">2. </span>
<abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> results</h2>

<p>A baby without <abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> or <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr> may be visualised as having 2 informative peak areas. This is known as 1:1 peak ratio.</p>

<p>A baby with <abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> or <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr> may be visualised either as having:</p>

<ul>
  <li>an extra peak, known as tri-allelic ratio</li>
  <li>a 2:1 peak ratio, known as a bi-allelic ratio</li>
</ul>

<h2>
<span class="number">3. </span>
<abbr title="prenatal diagnosis">PND</abbr> following a higher chance result from the combined or quadruple test or <abbr title="non-invasive pre-natal testing">NIPT</abbr>
</h2>

<p>For most women, the <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> result will be accurate for both <abbr title="chorionic villus sampling">CVS</abbr> and amniocentesis.</p>

<p>The presence of a tri-allelic <abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> or <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr> result indicates the chromosomal condition was present at conception and reflects the genotype of the baby.</p>

<p>A bi-allelic <abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> or <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr> <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> result from a <abbr title="chorionic villus sampling">CVS</abbr> sample may indicate the presence of confined placental mosaicism (<abbr title="confined placental mosaicism">CPM</abbr>). This is a very rare occurrence, less than 0.5% of all <abbr title="chorionic villus sampling">CVS</abbr> samples. <abbr title="confined placental mosaicism">CPM</abbr> is the presence of a chromosomal condition in the placenta that is not present in the baby. Laboratory protocols minimise the risk of <abbr title="confined placental mosaicism">CPM</abbr> from a <abbr title="chorionic villus sampling">CVS</abbr> sample.</p>

<p>Where <abbr title="confined placental mosaicism">CPM</abbr> is suspected, the laboratory will perform further testing to interpret the initial <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> result. This may be a karyotype to count the chromosomes or a further <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> on cultured cells.</p>

<p>There are 2 possible scenarios if the laboratory reports a bi-allelic <abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> or <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr> <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> result from a <abbr title="chorionic villus sampling">CVS</abbr> sample indicating <abbr title="confined placental mosaicism">CPM</abbr>.</p>

<h3>
<span class="number">3.1 </span>Scenario 1</h3>

<p><abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> or <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr> is suspected with findings on ultrasound scan consistent with any of these conditions.</p>

<p>In this scenario, healthcare professionals should discuss pregnancy options with the woman, as further testing is not always required.</p>

<h3>
<span class="number">3.2 </span>Scenario 2</h3>

<p><abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> or <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr> is suspected with no unexpected findings on ultrasound scan consistent with any of these conditions.</p>

<p>In this scenario, further testing on cultured cells is performed to interpret the initial <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> result. This is to exclude the possibility of <abbr title="confined placental mosaicism">CPM</abbr>. The offer of a further invasive test (amniocentesis) may be recommended after the analysis of the cultured cells.</p>

<p>Results from the cultured cells must be received and discussed with the woman before any decisions are made regarding pregnancy options including continuing or terminating the pregnancy.</p>

<h3>
<span class="number">3.3 </span>Future pregnancies</h3>

<p>Following a <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> result that shows evidence the baby has <abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> or <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr>, a karyotype test may also be performed. This is to give parents information about the chance of having another baby with one of these conditions. In this situation, decisions about the current pregnancy do not need to be delayed until the karyotype test results are known.</p>

<h2>
<span class="number">4. </span>
<abbr title="prenatal diagnosis">PND</abbr> following unexpected structural findings on the 20-week screening scan</h2>

<p>There are 2 clinical management options depending on the <abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> result.</p>

<h3>
<span class="number">4.1 </span>Scenario 1</h3>

<p><abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> result indicates <abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> or <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr>.</p>

<p>In this case, healthcare professionals should discuss pregnancy options with the woman including continuing or terminating the pregnancy.</p>

<h3>
<span class="number">4.2 </span>Scenario 2</h3>

<p><abbr title="quantitative fluorescence polymerase chain reaction">QF-PCR</abbr> result does not indicate <abbr title="trisomy 21 (Down's syndrome)">T21</abbr>, <abbr title="trisomy 18 (Edward's syndrome)">T18</abbr> or <abbr title="trisomy 13 (Patau's syndrome)">T13</abbr>.</p>

<p>In this case, management of ongoing diagnostic investigations is not within the remit of the NHS <abbr title="fetal anomaly screening programme">FASP</abbr>. Local guidance should be in place, for example, use of microarray or (R21) prenatal exome testing with a fetal anomaly gene panel in line with <a class="govuk-link" href="https://www.acgs.uk.com/quality/best-practice-guidelines/" rel="external">Association of Clinical Genomic Science (<abbr title="Association of Clinical Genomic Science">ACGS</abbr>) best practice guidelines</a> and the <a class="govuk-link" href="https://www.england.nhs.uk/publication/national-genomic-test-directories/" rel="external">NHS National Genomic Test Directory</a>.</p>

<h2>
<span class="number">5. </span>Prenatal diagnosis results</h2>

<p>All providers should have written guidance for the communication of <abbr title="prenatal diagnosis">PND</abbr> results. The process for communicating <abbr title="prenatal diagnosis">PND</abbr> results should be discussed and agreed with the woman before the procedure.</p>

<p>All women must be informed of the <abbr title="chorionic villus sampling">CVS</abbr> or amniocentesis result by an appropriately trained healthcare professional.</p>

<p>When a <abbr title="chorionic villus sampling">CVS</abbr> or amniocentesis is performed at a tertiary-level centre, that centre should provide written results to the referring healthcare professional. The woman should be informed of <abbr title="prenatal diagnosis">PND</abbr> results as per local guidelines.</p>

<p><a class="govuk-link" href="https://www.gov.uk/government/publications/fetal-anomaly-screening-programme-standards/standards-valid-from-1-april-2018#fasp-s09-diagnosisintervention-diagnostic-tests-fetal-anomaly-screening">Diagnosis/intervention standard <abbr title="fetal anomaly screening programme">FASP</abbr>-S09</a> outlines expected test turnaround times for <abbr title="prenatal diagnosis">PND</abbr> results.</p>

<h3>
<span class="number">5.1 </span>When <abbr title="prenatal diagnosis">PND</abbr> results show the baby does not have a condition screened for</h3>

<p>The woman should be informed of the result and continue with antenatal care. The outcome of the pregnancy should be reported to <a class="govuk-link" href="https://www.gov.uk/guidance/the-national-congenital-anomaly-and-rare-disease-registration-service-ncardrs">National Congenital And Rare Diseases Registration Service</a> (<abbr title="National Congenital and Rare Diseases Registration Service">NCARDRS</abbr>).</p>

<h3>
<span class="number">5.2 </span>When <abbr title="prenatal diagnosis">PND</abbr> results show the baby has a condition screened for</h3>

<p>A discussion of the results with an appropriately trained healthcare professional should be offered. Women should be supported to make <a class="govuk-link" href="/government/publications/fetal-anomaly-screening-programme-handbook/overview#choice">personal informed choices</a> about their ongoing care and pregnancy options.</p>

<h2>
<span class="number">6. </span>Pregnancy outcome audit</h2>

<p><a class="govuk-link" href="https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg8/" rel="external">Royal College of Obstetricians and Gynaecologists (<abbr title="Royal College of Obstetricians and Gynaecologists">RCOG</abbr>) guidelines</a> recommend every department performing <abbr title="chorionic villus sampling">CVS</abbr> and amniocentesis should maintain a register of procedures performed and the pregnancy outcome.</p>

<p>For audit purposes, pregnancy outcome forms should be completed and returned to the screening laboratory, or the locally agreed collating centre for all suspected and confirmed conditions. This should be done at the end of the pregnancy. Providers should develop a pathway for the completion and return of pregnancy outcome forms to the centre collecting the data.</p>

<p>Outcome information should be reported to <abbr title="National Congenital and Rare Diseases Registration Service">NCARDRS</abbr> for quality and monitoring of the NHS <abbr title="fetal anomaly screening programme">FASP</abbr>.</p>

</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" focusable="false" height="17" viewBox="0 0 13 17" width="13" xmlns="http://www.w3.org/2000/svg">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>